Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease.

Bastida G, Nos P, Aguas M, Beltrán B, Rubín A, Dasí F, Ponce J.

Aliment Pharmacol Ther. 2005 Nov 1;22(9):775-82.

2.

Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.

Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J.

Aliment Pharmacol Ther. 2008 Sep 15;28(6):734-41.

PMID:
19145729
3.

Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients.

Gisbert JP, Luna M, González-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Maté J.

Inflamm Bowel Dis. 2007 Sep;13(9):1106-14.

PMID:
17455203
4.

A histopathologic pattern of centrilobular hepatocyte injury suggests 6-mercaptopurine-induced hepatotoxicity in patients with inflammatory bowel disease.

Masia R, Pratt DS, Misdraji J.

Arch Pathol Lab Med. 2012 Jun;136(6):618-22. doi: 10.5858/arpa.2011-0214-OA.

PMID:
22646267
5.

Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.

Leong RW, Gearry RB, Sparrow MP.

Expert Opin Drug Saf. 2008 Sep;7(5):607-16. doi: 10.1517/14740338.7.5.607 . Review.

PMID:
18759713
6.

Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.

Wong DR, Coenen MJ, Derijks LJ, Vermeulen SH, van Marrewijk CJ, Klungel OH, Scheffer H, Franke B, Guchelaar HJ, de Jong DJ, Engels LG, Verbeek AL, Hooymans PM; TOPIC Recruitment Team.

Aliment Pharmacol Ther. 2017 Feb;45(3):391-402. doi: 10.1111/apt.13879. Epub 2016 Dec 12.

PMID:
27943397
7.

Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.

van Asseldonk DP, Seinen ML, de Boer NK, van Bodegraven AA, Mulder CJ.

J Crohns Colitis. 2012 Feb;6(1):95-101. doi: 10.1016/j.crohns.2011.07.009.

PMID:
22261533
8.

Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.

Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, van der Woude CJ, de Jong DJ, Mulder CJ, van Elburg RM, van Bodegraven AA; Dutch Initiative on Crohn and Colitis.

Gut. 2014 Mar;63(3):451-7. doi: 10.1136/gutjnl-2012-303615. Epub 2013 Feb 19.

PMID:
23424097
9.

Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review.

Gisbert JP, González-Lama Y, Maté J.

Am J Gastroenterol. 2007 Jul;102(7):1518-27. Epub 2007 Mar 27. Review.

PMID:
17391318
10.

Azathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and Outcomes.

Björnsson ES, Gu J, Kleiner DE, Chalasani N, Hayashi PH, Hoofnagle JH; DILIN Investigators.

J Clin Gastroenterol. 2017 Jan;51(1):63-69.

11.

Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.

Shaye OA, Yadegari M, Abreu MT, Poordad F, Simon K, Martin P, Papadakis KA, Ippoliti A, Vasiliauskas E, Tran TT.

Am J Gastroenterol. 2007 Nov;102(11):2488-94. Epub 2007 Aug 31.

PMID:
17764490
12.

Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.

Kreijne JE, Seinen ML, Wilhelm AJ, Bouma G, Mulder CJ, van Bodegraven AA, de Boer NK.

Ther Drug Monit. 2015 Dec;37(6):797-804. doi: 10.1097/FTD.0000000000000213.

PMID:
25853923
13.

TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease.

Stocco G, Martelossi S, Barabino A, Fontana M, Lionetti P, Decorti G, Malusà N, Bartoli F, Fezzi M, Giraldi T, Ventura A.

Dig Liver Dis. 2005 Dec;37(12):940-5. Epub 2005 Sep 30.

PMID:
16202677
14.

Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.

López-Martín C, Chaparro M, Espinosa L, Bejerano A, Maté J, Gisbert JP.

Gastroenterol Hepatol. 2011 Jun-Jul;34(6):385-92. doi: 10.1016/j.gastrohep.2011.03.023. Epub 2011 May 25.

PMID:
21616565
15.

Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?

Fangbin Z, Xiang G, Minhu C, Liang D, Feng X, Min H, Pinjin H.

Ther Drug Monit. 2012 Dec;34(6):695-701. doi: 10.1097/FTD.0b013e3182731925.

PMID:
23149442
16.

Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.

González-Lama Y, Bermejo F, López-Sanromán A, García-Sánchez V, Esteve M, Cabriada JL, McNicholl AG, Pajares R, Casellas F, Merino O, Carpio D, Vera MI, Muñoz C, Calvo M, Benito LM, Bujanda L, García-Fernández FJ, Ricart E, Ginard D, Velasco M, Carneros JA, Manceñido N, Calvo M, Algaba A, Froilan C, Cara C, Maté J, Abreu L, Gisbert JP; "Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)".

Aliment Pharmacol Ther. 2011 Sep;34(5):544-54. doi: 10.1111/j.1365-2036.2011.04756.x. Epub 2011 Jul 3.

17.

Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment.

Schröder T, Schmidt KJ, Olsen V, Möller S, Mackenroth T, Sina C, Lehnert H, Fellermann K, Büning J.

Eur J Gastroenterol Hepatol. 2015 Jun;27(6):698-704. doi: 10.1097/MEG.0000000000000350.

PMID:
25923946
18.

Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.

Gómez-García M, Cabello-Tapia MJ, Sánchez-Capilla AD, De Teresa-Galván J, Redondo-Cerezo E.

World J Gastroenterol. 2013 Aug 14;19(30):4877-86. doi: 10.3748/wjg.v19.i30.4877.

19.

Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.

Daperno M, Sostegni R, Canaparo R, Serpe L, Lavagna A, Crocellà L, Castagno F, Vernetto A, Rigazio C, Ercole E, D'Antico S, Pera A, Zara G, Rocca R.

Aliment Pharmacol Ther. 2009 Oct 15;30(8):843-53. doi: 10.1111/j.1365-2036.2009.04106.x. Epub 2009 Jul 24.

20.

Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.

Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV Jr, Peyrin-Biroulet L, Blonski WC, Van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR.

Clin Gastroenterol Hepatol. 2015 May;13(5):847-58.e4; quiz e48-50. doi: 10.1016/j.cgh.2014.05.015. Epub 2014 May 28.

PMID:
24879926

Supplemental Content

Support Center